SEP 16, 2015 08:00 AM PDT

Diversity-Oriented Synthesis for Discovery of Novel Therapeutics

Speakers
  • Vice President, Discovery Chemistry, H3 Biomedicine
    Biography
      Dr. Lisa Marcaurelle joined H3 Biomedicine as Vice President of Discovery Chemistry in April 2011, from the Broad Institute, where she was Director of Synthetic Chemistry in the Chemical Biology Platform.

      During her four years at the Broad Institute, Lisa established a synthetic platform for the large-scale production of diversity-oriented synthesis (DOS) libraries, generating a collection of more than 100,000 small molecules for use in high-throughput screening. While at the Broad, Lisa also served as a Project Leader for the Harvard/Broad Center for Chemical Methodology and Library Development (CMLD). Prior to joining the Broad, she worked at Infinity Pharmaceuticals from 2002 to 2007, where she was engaged in the synthesis of numerous DOS libraries and participated in oncology-focused medicinal chemistry efforts.

      Lisa completed her post-doctoral research at the Massachusetts Institute of Technology, working with Professor Peter Seeberger. She obtained a Ph.D. in chemistry from the University of California, Berkeley, working under the guidance of Professor Carolyn Bertozzi. Lisa earned a B.A. in chemistry from the College of the Holy Cross in Worcester, MA.

    Abstract:
    Recent evidence demonstrating the importance of structural complexity in advancing compounds to the clinic points to the need for enhancing small molecule screening collections with sp3-rich compounds. The development of diversity-oriented synthesis (DOS) strategies for accessing libraries of sp3-rich compounds containing one or more stereogenic centers will be presented, focusing on library synthesis efforts at H3 Biomedicine as well as previous work at the Broad Institute. The DOS libraries which have been created, span a broad range of molecular frameworks, including macrocycles and medium-sized rings, as well as fused-, bridged- and spirocyclic- ring systems. Preliminary results of high-throughput screening of the H3 compound collection will be discussed, with an emphasis on the identification of novel modulators of pre-mRNA splicing.

    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    SEP 12, 2017 08:00 AM PDT
    SEP 12, 2017 08:00 AM PDT
    DATE: September 12, 2017TIME: 8:00am PT, 11:00am ETEvery year, millions of dollars are wasted on poorly characterized and performing antibodies.  Key researchers in the antibody co...
    AUG 30, 2018 11:00 AM EDT
    C.E. CREDITS
    AUG 30, 2018 11:00 AM EDT
    DATE: August 30, 2018TIME: 11:00am EDT, 5:00pm CEST The need to quantify urine is valuable because it provides information on chemicals that the body makes naturally, as well...
    AUG 30, 2018 10:00 AM CEST
    C.E. CREDITS
    AUG 30, 2018 10:00 AM CEST
    DATE: August 30, 2018TIME:  10:00am CEST, 4:00pm CST The need to quantify urine is valuable because it provides information on chemicals that the body makes naturall...
    NOV 15, 2018 10:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 15, 2018 10:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
    Loading Comments...